Cargando…
Chikungunya: vaccines and therapeutics
Chikungunya virus (CHIKV) has come to prominence as a global, re-emerging pathogen over the last two decades, progressing from sporadic, remote outbreaks to worldwide explosive epidemics. From contained, though considerable, outbreaks in the southern Indian Ocean, parts of South America and the Cari...
Autores principales: | Tharmarajah, Kothila, Mahalingam, Suresh, Zaid, Ali |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000 Research Limited
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728195/ https://www.ncbi.nlm.nih.gov/pubmed/29259782 http://dx.doi.org/10.12688/f1000research.12461.1 |
Ejemplares similares
-
Liposomal Delivery of the RNA Genome of a Live-Attenuated Chikungunya Virus Vaccine Candidate Provides Local, but Not Systemic Protection After One Dose
por: Abeyratne, Eranga, et al.
Publicado: (2020) -
Interleukin-17 contributes to Ross River virus-induced arthritis and myositis
por: Mostafavi, Helen, et al.
Publicado: (2022) -
Attenuation and Stability of CHIKV-NoLS, a Live-Attenuated Chikungunya Virus Vaccine Candidate
por: Abeyratne, Eranga, et al.
Publicado: (2018) -
Mutation of the N-Terminal Region of Chikungunya Virus Capsid Protein: Implications for Vaccine Design
por: Taylor, Adam, et al.
Publicado: (2017) -
Fighting back against chikungunya
por: Rudd, Penny A, et al.
Publicado: (2015)